ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Acquire the skills, knowledge and hands-on experience for a career as a Pharmaceutical Analyst in Industry or Academia. WHO ARE YOU? You are probably a recent physical or life sciences graduate – ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

A pharmaceutical giant that made a splashy, incentive-backed entrance to Tampa over 10 years ago plans to slash its office ...

Bristol Myers Squibb Co. closed $9.72 below its 52-week high ($59.46), which the company reached on September 21st.

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...

1 At the same time, there are no fewer than 6 lawsuits currently pending against the IRA, filed by Merck, the US Chamber of ...